The content on this site is intended for healthcare professionals only
Prof Martin Wermke speaks to ecancer about results from the Phase Ia RevSTAR-123 study evaluating AVC-201-01, a switchable allogeneic CD123-targeted CAR-T therapy, in patients with relapsed, refractory, or MRD-positive acute myeloid leukaemia.
He explains that this off-the-shelf CAR-T platform is designed to overcome challenges associated with autologous CAR-T therapies in AML while allowing treatment activity to be controlled through a bispecific adaptor molecule.
Prof Wermke reports a favourable safety profile, with no treatment-related mortality, neurotoxicity, or graft-versus-host disease observed.
He states that anti-leukaemic activity was seen at the highest dose levels, including complete remissions, MRD conversions, and ongoing responses.
First-in-human study of in vivo CAR-T therapy shows promising activity in relapsed or refractory B-cell non-Hodgkin lymphoma
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone
Novel biomarkers in myeloma: CTCs and cfDNA
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma
